SEC Filing Analysis: Revolution Medicines, Inc.

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Vanguard Group reports a reduction of beneficial ownership to 0% specifically due to an internal corporate realignment and change in reporting structure, not a market liquidation.
• Market Impact: Neutral; the filing is administrative in nature.

Company Information

Field	Value
Company	Revolution Medicines, Inc.
CIK	0001628171
Industry	Biological Products
Market Cap	$18.80 Billion
Shares Outstanding	198,170,000

Investor Information

Field	Value
Name	The Vanguard Group
CIK	0000102909
Type	Investment Adviser
Location	Malvern, PA

Transaction Details

Field	Value
Form Type	SCHEDULE 13G/A
Filing Date	2026/03/27
Shares Owned After	0
Percent of Class	0%
Ownership Type	N/A

Financial Impact Assessment

Transaction Materiality

Metric	Value
Post-Transaction Ownership	0 shares (0% of outstanding)
Materiality Assessment	Low (Technical/Administrative)

Impact Evaluation

• Market Cap Context: With an $18.80B market cap, Revolution Medicines is a large-cap biotech entity. Institutional holdings are typically significant.
• Ownership Concentration: While this specific filing shows 0%, the footnotes indicate that Vanguard subsidiaries now report separately. The aggregate exposure of Vanguard-related entities may remain unchanged.
• Transaction Significance: The filing explicitly states that due to an internal realignment on January 12, 2026, The Vanguard Group, Inc. no longer has beneficial ownership over securities owned by its subsidiaries. These subsidiaries will report on a disaggregated basis.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a technical amendment (Form 13G/A) clarifying a change in legal reporting structure for the investment adviser, rather than a signal of bearish sentiment or a disposal of assets for investment reasons.

Volume & Sentiment

• Expected Volume Impact: Negligible.
• Sentiment Indicator: Neutral. Algorithms scraping only the "0 shares" figure might briefly misinterpret this, but human analysis confirms it is administrative.

Additional Context

Transaction Notes

• Special Circumstances: The filing includes a specific comment: "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment... certain subsidiaries... will report beneficial ownership separately... The Vanguard Group, Inc. no longer has... beneficial ownership over securities beneficially owned by such subsidiaries."
• Regulatory Context: This reporting is done in reliance on SEC Release No. 34-39538 (January 12, 1998).